Medicenna Set to Showcase Breakthrough Cancer Therapies at Two Major Conferences

Medicenna's Upcoming Presentations Highlight Innovative Cancer Therapies

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a pioneering clinical-stage immunotherapy company known for its advanced research in cancer treatments, is excited to announce its participation in two eminent scientific conferences. The company plans to present significant pre-clinical findings at the upcoming Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS). These presentations will showcase the latest developments in their IL-2 Superkine technology, a critical advancement in immunotherapy for cancer.

Key Details About the Presentations

During the 29th Annual SNO Meeting, taking place from November 21 to 24, Medicenna will deliver an impressive presentation focused on MDNA11 and its role in the treatment of glioblastoma. This event will host numerous leading experts in the field and serve as a platform for the latest advancements in neuro-oncology.

29th Annual SNO Meeting Presentation Details

Presentation Title: Invigorating effector immune cells with highly selective IL-2R agonists and potential synergy with tumor targeting therapeutics for treatment of glioblastomas
Session Date: Friday, November 22, 2024
Session Time: 7:30 – 9:30 PM CT
Abstract Number: IMMU-62

Exploration at the 2024 SABCS

The following month, at the 2024 SABCS from December 10 to 13, Medicenna will further expand on its groundbreaking research by discussing the applications of MDNA11 in aggressive metastatic breast cancer models.

2024 SABCS Presentation Details

Presentation Title: Neo-adjuvant administration of MDNA11, a long-acting IL-2 Superkine, prevents metastasis, protects against tumor rechallenges and provides long-term survival in an orthotopic model of breast cancer
Session Date: Thursday, December 12, 2024
Session Time: 12:00 – 2:00 PM CT
Abstract: SESS-1335

Innovative Features of MDNA11

MDNA11 represents a revolutionary class of treatment, described as an intravenous, long-acting 'beta-enhanced not-alpha' IL-2 Superkine. This innovative therapy has been specifically engineered to address the limitations of existing IL-2 treatments. It primarily energizes immune effector cells, including CD8+ T and NK cells, while minimizing the activation of immunosuppressive Tregs. The unique capabilities of MDNA11 stem from seven strategic mutations and genetic fusion to a human albumin scaffold, enhancing its pharmacokinetic profile and concentrating in tumor areas.

About Medicenna Therapeutics

Medicenna is on the forefront of immunotherapy research, focusing on developing next-generation Superkines that are designed for superior therapeutic effects. Its noteworthy advancements include MDNA11, which ensures enhanced binding to CD122 (IL-2 receptor beta) without engaging CD25 (IL-2 receptor alpha). This delicate balance allows for the preferential stimulation of tumor-fighting T cells while limiting activation of non-beneficial immune responses.

Further Research and Development

Beneath its robust pipeline, Medicenna is developing other innovative products, such as the IL-4 Empowered Superkine, bizaxofusp. This specific therapy has already garnered significant attention, having participated in multiple clinical trials, further solidifying Medicenna's commitment to tackling some of the most challenging cancers, including glioblastoma.

Stay Connected with Medicenna

Medicenna encourages those interested in learning more about their innovative therapies and upcoming presentations to visit their official website. Their ongoing research aims to enrich the treatment landscape for cancer and provide better outcomes for patients worldwide.

Frequently Asked Questions

What is the primary focus of Medicenna's research?

Medicenna focuses on developing novel immunotherapy treatments, specifically IL-2 and related Superkines, to enhance cancer treatment outcomes.

Where will Medicenna present its findings?

Medicenna will present its research at the 29th Annual SNO Meeting and the 2024 SABCS, both prominent events in the field of oncology.

What is MDNA11?

MDNA11 is a long-acting IL-2 Superkine designed to preferentially activate immune effector cells while avoiding the activation of immunosuppressive Tregs.

How is MDNA11 expected to impact breast and brain cancer treatment?

MDNA11 aims to prevent cancer metastasis and enhance the overall survival of patients, as evidenced by pre-clinical studies presented at major conferences.

How can investors learn more about Medicenna?

Investors can explore more about Medicenna’s ongoing projects, conferences, and breakthroughs by visiting their official website or reaching out via their investor relations contact.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.